      5 printing
      2 confounded
      1 internationallyaccepted
      1 fivecent
<<CONTENT>>
shares hit by ms drug suspension

shares in elan and biogen idec plunged on monday as the firms suspended sales of new multiple sclerosis drug tysabri after a patients death in the us

on the new york stock exchange shares in irelandbased elan lost 70% while us partner biogen idec shed 43% the firms took action after the death from a central nervous system disease and a suspected case of the condition the cases cited involved the use of both tysabri and avonex biogen idecs existing multiple sclerosis drug the companies said they have no reports of the rare condition  progressive multifocal leukoencephalopathy pml  in patients taking either tysabri or avonex alone tysabri was approved for use in the us last november and was widely tipped to become the worlds leading multiple sclerosis treatment

the companies will work with clinical investigators to evaluate tysabritreated patients and will consult with leading experts to better understand the possible risk of pml the two firms said in a statement the outcome of these evaluations will be used to determine possible reinitiation of dosing in clinical trials and future commercial availability

analysts had believed the product would provide a new growth opportunity for biogen idec which had faced increased competition from rivals to avonex elan once the biggest firm on the irish stock exchange was also expected to receive a boost from the new product an inquiry into elans accounts in 2002 brought the group close to bankruptcy but the firm has been rebuilding itself since with its share price increasing by almost fourfold last year most of the value in the company was in tysabri said ian hunter at goodbody stockbrokers in dublin now theres a question mark over it elan finished down 1890 at 8 while biogen fell 2863 to 3865

 shares in uk pharmaceutical firm phytopharm closed down 1984% at 1515 pence on the london stock exchange on monday after it said a partner was set to pull out of a deal on an experimental alzheimers disease treatment phytopharm said japans yamanouchi pharmaceutical was likely to end a licensing agreement prompting analysts to raise questions over the level of its future cash reserves
